Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Schizophrenia & Other Psychotic Disorders Schizophrenia & Other Psychotic Disorders for September/October 2020 Risk factors for QTc prolongation during amisulpride therapy in schizophrenia, Schizophrenia: Reinitiating clozapine can be considered in patients who have previously discontinued it, Elevated IL-18 levels in patients with schizophrenia, Schizophrenia: Antipsychotic choice may influence driving-related cognitive performance, Treatment-resistant schizophrenia: Is slower-than-recommended titration of clozapine beneficial?, More must reads Schizophrenia & Other Psychotic Disorders for July/August 2020 Chronic smoking tied to cognitive impairment in patients with schizophrenia, Brexpiprazole for severe symptoms of schizophrenia, Higher serum prolactin linked to aggression in female patients with schizophrenia, Clozapine vs other antipsychotic adherence in schizophrenia, Methadone maintenance treatment as a predictor of long-term survival in schizophrenia, More must readsSchizophrenia & Other Psychotic Disorders for May/June 2020 Omega-3 fatty acids improve cognitive function in patients with schizophrenia and metabolic syndrome, Chronic schizophrenia: Do BMI and orexin-A levels play a role?, Risperidone lowers serum interleukin-6 levels in schizophrenia, Schizophrenia and sexual dysfunction: Is there a link?, Genetic liability to schizophrenia tied to childhood trauma , More must readsSchizophrenia & Other Psychotic Disorders for March/April 2020 Exposure to air pollution tied to risk of developing schizophrenia, Paliperidone palmitate long-acting injectable may improve negative symptoms, Sarcosine may improve clinical symptoms in schizophrenia, Cigarette smoking a risk factor for schizophrenia, Olanzapine/samidorphan combo safe and effective in acute exacerbation, More must readsSchizophrenia & Other Psychotic Disorders for January/February 2020 Risk Factors Mediating Adverse Birth Outcomes in Women With Schizophrenia, Serum Cytokine Levels Can Predict Therapeutic Efficacy in Patients With Schizophrenia, Lumateperone is a Potential Treatment Option for Schizophrenia, Long-Acting Antipsychotic Injections Prevent Readmissions in Patients With Schizophrenia, N-Acetylcysteine is an Effective Adjunct Therapy for Schizophrenia, More must readsPages1 2 3 4 5 6 7 last ยป
